AEterna Zentaris (AEterna Zentaris) Accounts Receivable : $0.07 Mil (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is AEterna Zentaris Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. AEterna Zentaris's accounts receivables for the quarter that ended in Dec. 2023 was $0.07 Mil.

Accounts receivable can be measured by Days Sales Outstanding. AEterna Zentaris's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 50.53.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. AEterna Zentaris's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $3.15.

AEterna Zentaris Accounts Receivable Historical Data

The historical data trend for AEterna Zentaris's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Accounts Receivable Chart

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

Get a 7-Day Free Trial

0.21

1.19

0.88

0.40

0.07

AEterna Zentaris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Receivable	Get a 7-Day Free Trial															0.40	0.56	0.19	0.55	0.07

AEterna Zentaris Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

AEterna Zentaris Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

AEterna Zentaris's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.067	/	0.121	*	91
=	50.53

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), AEterna Zentaris's accounts receivable are only considered to be worth 75% of book value:

AEterna Zentaris's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(34.016	+	0.75 * 0.067	+	0.5 * 0.066	-	18.82
-	0	-	0)	/	4.85588
=	3.15

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

AEterna Zentaris Accounts Receivable Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (AEterna Zentaris) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (NAS:AEZS) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

ET8:Germany ET8:Germany AEZS:Canada

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.